Oral nicotine pouches, a tobacco leaf-free product marketed as an alternative to cigarettes, do little to curb current smokers’ nicotine cravings, according to a study.
Preliminary data from Arm A1 of the phase II EDGE-Gastric study showed promising overall response rate and six-month progression-free-survival results, irrespective of PD-L1 expression.
Positive high-level results from the EMERALD-1 phase III trial showed Imfinzi (durvalumab) in combination with transarterial chemoembolization, or TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival versus TACE alone in patients with hepatocellular carcinoma eligible for embolization. The trial continues to follow the secondary endpoint of overall survival.
A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactions between tumor cells and immune components of the microenvironment can impact treatment responses and outcomes in patients newly diagnosed with multiple myeloma who undergo combination treatments that include targeted immunotherapy.
UCLA scientists developed a novel method to engineer more powerful immune cells that can potentially be used for “off-the-shelf” cell therapy to treat challenging cancers.
An international collaboration led by USC compiled the most comprehensive list of genetic variants associated with prostate cancer risk through a whole-genome analysis that ranks as the largest and most diverse investigation into prostate cancer genetics yet.
An international phase III clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS G12C experienced superior progression-free survival rates compared to standard of care when offered a combination treatment of KRAS inhibitor sotorasib and monoclonal antibody panitumumab.
Part 1 of the phase III RUBY trial of Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel) followed by dostarlimab as a single agent, compared to placebo plus chemotherapy followed by placebo in adult patients with primary advanced or recurrent endometrial cancer produced positive primary results from a planned analysis.
Children with Down syndrome have an increased risk of developing acute lymphoblastic leukemia and experience higher rates of relapse and treatment toxicity. In recent decades, new therapies have improved outcomes for the general population, but outcomes for children with Down syndrome have lagged and have not been reported for contemporary treatment regimens.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found that the two test results differ because there are underlying subtle differences in the cells that make up an endometrial cancerous tumor.
